Greetings from the National Library of Medicine and MedlinePlus.gov
Regards to all our listeners!
I'm Rob Logan, Ph.D. senior staff National Library of Medicine for Donald Lindberg, M.D, the Director of the U.S. National Library of Medicine.
Prostate removal surgery does not save lives compared to active surveillance for most men with localized prostate cancer, suggest a comprehensive study and accompanying editorial recently published in the New England Journal of Medicine.
In a 15-year clinical trial of 731 American men with localized prostate cancer, there was not a statistically meaningful difference in mortality between those who were randomly assigned to obtain prostate removal surgery, and those who randomly received active surveillance, or what is sometimes called ‘watchful waiting.’
Localized prostate cancer occurs when a biopsy reveals cancer is contained within the prostate gland area. Localized prostate cancer often is an example of early stage prostate cancer; both of which are detected sometimes by a PSA screening test.
About half of the study’s 731 male participants died; 171 deaths occurred among those randomly assigned to the prostate removal surgical group and 183 died in the active surveillance group. The study’s 21 authors report these mortality differences are not statistically significant.
However, most participant deaths were not from prostate cancer. Only 52 men (or about seven percent) of the 354 trial participants with localized prostate cancer died from prostate cancer. Similarly among those who died from prostate cancer, the mortality rates between the prostate removal and active surveillance groups were not statistically meaningful.
The only meaningful differences between the prostate removal surgery and active surveillance groups occurred within a small group with localized prostate cancer who also had the highest initial PSA test scores. Among these participants, there were 13 percent fewer deaths in the surgery compared to the active surveillance group (which is statistically significant).
The American Cancer Society reports about 28,000 American men die annually and 242,000 new cases of prostate cancer are estimated to occur each year. PSA (or prostate specific antigen) blood tests have been a widely used screening tool in prostate cancer checkups for men after age 40.
The clinical trial, which took place from 1994-2002, was conducted by the Prostate Cancer Intervention versus Observation Trial Study group from multiple university medical centers throughout the U.S. The research was co-sponsored by the Agency for Healthcare Research and Quality, the National Cancer Institute, and the U.S. Department of Veterans Affairs.
An accompanying editorial suggests the current study is among the most comprehensive assessments of surgery versus surveillance options for prostate cancer patients to date. However, the editorial’s authors add the aggregate findings from the current and similar studies do not provide definitive answers about the wisdom of surgery versus surveillance, or broader issues such as the wisdom of using PSA blood tests to screen for prostate cancer.
In a recent podcast, we discussed the U.S. Preventive Services Task Force’s recent recommendation PSA blood tests should not be used to screen for prostate cancer in men. The Task Force (an independent panel of experts authorized by Congress to recommend preventive services for patients) found the PSA test’s risks outweighed its benefits.
While current research may not resolve the uncertainty in making some prostate cancer clinical decisions, the editorial’s authors note there is sufficient evidence to suggest a path for physicians and patients to follow.
The editorial’s authors ask rhetorically and we quote; “what is a rational approach to control this disease’ (end of quote)? They respond (and we quote): ‘The most efficient solution will probably include biopsy only for men with lethal cancer, treatment focused on this type of cancer, and individualized treatment approaches’ (end of quote).
The authors conclude prostrate cancer is a spectrum of diseases and effective treatment should require aggressive interventions based on high-risk tumors.
MedlinePlus.gov’s prostate cancer health topic page covers some of the risks and benefits of PSA, and prostate cancer screening, and treatment. A helpful explanation about the risks and benefits of treatment options including surgery and surveillance for localized prostate cancer (provided by Agency for Healthcare Research and Quality) can be found in the ‘prevention/screening’ section of MedlinePlus.gov’s prostate cancer health topic page. The U.S. Preventive Task Force’s recent prostate cancer screening recommendations also are available in the ‘prevention/screening’ section.
Additional background information about localized prostate cancer (also provided by the Agency for Healthcare Research and Quality) is available in the ‘health check tools’ section. An introduction to treatment options for men with early-stage prostate cancer (provided by the National Cancer Institute) can be found in the ‘treatment’ section.
MedlinePlus.gov’s prostate cancer health topic page additionally contains links to the latest pertinent journal research articles, which are available in the ‘journal articles’ section. Links to related clinical trials that may be occurring in your area are available in the ‘clinical trials’ section. From the prostate cancer health topic page, you can sign up to receive email updates with links to new information as it becomes available on MedlinePlus.
To find MedlinePlus.gov’s prostate cancer health topic page, type ‘prostate cancer’ in the search box on MedlinePlus.gov’s home page, then, click on ‘Prostate cancer (National Library of Medicine).’
Before I go, this reminder… MedlinePlus.gov is authoritative. It's free. We do not accept advertising …and is written to help you.
To find MedlinePlus.gov, just type in 'MedlinePlus.gov' in any web browser, such as Firefox, Safari, Netscape, Chrome or Explorer. To find Mobile MedlinePlus.gov, just type 'Mobile MedlinePlus' in the same web browsers.
We encourage you to use MedlinePlus and please recommend it to your friends. MedlinePlus is available in English and Spanish. Some medical information is available in 43 other languages.
Your comments about this or any of our podcasts are always welcome. We welcome suggestions about future topics too!
Please email Dr. Lindberg anytime at: NLMDirector@nlm.nih.gov
That's NLMDirector (one word) @nlm.nih.gov
A written transcript of recent podcasts is available by typing 'Director's comments' in the search box on MedlinePlus.gov's home page.
The National Library of Medicine is one of 27 institutes and centers within the National Institutes of Health. The National Institutes of Health is part of the U.S. Department of Health and Human Services.
A disclaimer – the information presented in this program should not replace the medical advice of your physician. You should not use this information to diagnose or treat any disease without first consulting with your physician or other health care provider. I want to take the opportunity to wish you a very happy holiday season and a healthy New Year. The National Library of Medicine and the 'Director's Comments' podcast staff, including Dr. Lindberg, appreciate your interest and company – and we hope to find new ways to serve you in 2012.
I look forward to meeting you here next week.